/
Prothena Corporation plc ( Prothena or the Company ) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number…
The business is unprofitable at the operating level (-2216.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 92.8% YoY. Margins deteriorated 2102.1pp alongside, both lines moving the wrong way.
ROIC dropped from -22.80% to -43.11%, capital efficiency is deteriorating. Operating margin contracted 2102.1pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$58M
▼ -92.8% YoY
Net Income (TTM)
-$151M
▼ -99.6% YoY
Op. Margin
-205.43%
▼ -2102.1pp YoY
ROIC
-30.15%
▼ -20.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$81M
▼ -9.0% YoY
Net Debt
-$322M
Net Cash Position
Cash & Equiv.
$329M
5Y CAGR: +62.6%
Continue Research